MedTrace Logo

ERAP1,2 in Recalcitrant Warts

NCT06833164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-02-18

No results posted yet for this study

Summary

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Conditions

  • Warts

Interventions

DIAGNOSTIC_TEST

endoplasmic reticulum Aminopeptidase 1 and 2

endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA

DIAGNOSTIC_TEST

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ihab Y. Abdallah, MD · Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University

  • Nehad A.Fouad, MD · Professor of Microbiology and Immunology, Faculty of Medicine, Benha University

  • Ola S Ebrahim, MBBCh · Benha University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-03-20
Completion
2024-03-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833164 on ClinicalTrials.gov